Corrigendum: The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma

Front Oncol. 2020 Sep 25:10:591112. doi: 10.3389/fonc.2020.591112. eCollection 2020.

Fangling Cheng^{1

2}, Po Zhang^{1

2}, Qungen Xiao¹, Youwei Li^{1

2}, Minhai Dong^{1

2}, Heping Wang¹, Dong Kuang^{3

4}, Yue He¹, Qiuhong Duan⁵, Feng Mao¹, Baofeng Wang¹, Dongsheng Guo¹

¹ Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
² Chinese-German Lab of Molecular Neuro-oncology of Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
³ Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
⁴ Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
⁵ Department of Biochemistry and Molecular Biology, School of Basic Medicine, Huazhong University of Science and Technology, Wuhan, China.

Abstract

[This corrects the article DOI: 10.3389/fonc.2019.00447.].

Keywords: LRIG3; MET/PI3K/Akt pathway; glioblastoma; glioma; prognosis; soluble LRIG3.